Healthcare resource utilization and costs of letermovir for cytomegalovirus-prophylaxis after allogeneic hematopoietic cell transplantation in a real-world, multi-centre study in Germany. - Engelhard M; Wingen-Heimann SM; Classen AY; Blau IW; Bug G; Hebermehl C; Kraus S; Penack O; Rettig AR; Schmitt T; Steinbrunn T; Teschner D; et al. (The European journal of health economics : HEPAC : health economics in prevention and care, 2026)